Resultats de la cerca - Keith T. Flaherty

Refinar resultats
  1. 1
    Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma

    Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma per Keith T. Flaherty

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    MAP kinase signaling and inhibition in melanoma

    MAP kinase signaling and inhibition in melanoma per Ryan J. Sullivan, Keith T. Flaherty

    Publicat 2012
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

    BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance per Ryan J. Sullivan, Keith T. Flaherty

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    BRAF, a target in melanoma

    BRAF, a target in melanoma per Keith T. Flaherty, Grant A. McArthur

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Integrating BRAF/MEK inhibitors into combination therapy for melanoma

    Integrating BRAF/MEK inhibitors into combination therapy for melanoma per Keiran S.M. Smalley, Keith T. Flaherty

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    Targeting the RAS pathway in melanoma

    Targeting the RAS pathway in melanoma per Zhenyu Ji, Keith T. Flaherty, Hensin Tsao

    Publicat 2011
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

    Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways per Xue Bai, David E. Fisher, Keith T. Flaherty

    Publicat 2019
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    YAP in MAPK pathway targeted therapy resistance

    YAP in MAPK pathway targeted therapy resistance per Keith T. Flaherty, Jennifer A. Wargo, Trever G. Bivona

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  9. 9
    Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

    Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy per Jennifer A. Lo, David E. Fisher, Keith T. Flaherty

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be

    The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be per Ryan J. Sullivan, Patricia LoRusso, Keith T. Flaherty

    Publicat 2013
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  11. 11
    Mutation-driven drug development in melanoma

    Mutation-driven drug development in melanoma per Keith T. Flaherty, F. Stephen Hodi, Boris C. Bastian

    Publicat 2010
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  12. 12
    Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

    Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer per Jennifer A. Wargo, Zachary A. Cooper, Keith T. Flaherty

    Publicat 2014
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  13. 13
    Melanoma: New Insights and New Therapies

    Melanoma: New Insights and New Therapies per Vasiliki Nikolaou, Alexander Stratigos, Keith T. Flaherty, Hensin Tsao

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  14. 14
    Mechanisms of resistance to immune checkpoint inhibitors

    Mechanisms of resistance to immune checkpoint inhibitors per Russell W. Jenkins, David A. Barbie, Keith T. Flaherty

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  15. 15
    The Conundrum of Genetic “Drivers” in Benign Conditions

    The Conundrum of Genetic “Drivers” in Benign Conditions per Shumei Kato, Scott M. Lippman, Keith T. Flaherty, Razelle Kurzrock

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  16. 16
    Precision medicine for cancer with next-generation functional diagnostics

    Precision medicine for cancer with next-generation functional diagnostics per Adam A. Friedman, Anthony Letai, David E. Fisher, Keith T. Flaherty

    Publicat 2015
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  17. 17
    Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

    Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma per Neel M. Fofaria, Dennie T. Frederick, Ryan J. Sullivan, Keith T. Flaherty, Sanjay Srivastava

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition

    p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition per Zhenyu Ji, Ching Ni Njauw, Michael Taylor, Victor Neel, Keith T. Flaherty, Hensin Tsao

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

    BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape per Inna V. Fedorenko, Jennifer A. Wargo, Keith T. Flaherty, Jane L. Messina, Keiran S.M. Smalley

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    A Melanoma Molecular Disease Model

    A Melanoma Molecular Disease Model per Smruti J. Vidwans, Keith T. Flaherty, David E. Fisher, Jay M. Tenenbaum, Michael Travers, Jeff Shrager

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: